Profitelligence Profitelligence · Filing Ledger Search all insiders →

Insider Profile · SEC Form 4 Activity · Trailing 90 Days

Fairmount Healthcare Fund Ii L.p.

Over the trailing 90 days, Fairmount Healthcare Fund Ii L.p. (Director at Oruka Therapeutics, Inc.) traded $739.7M of stock (net selling $659.7M) across 5 companies, per 13 SEC Form 4 transactions.

Role
Director
Companies
ORKA SYRE CBIO JBIO VRDN
Window
Trailing 90 days · 13 transactions · CIK 1769651
Net activity
−$659.7M ($40.0M bought · $699.7M sold)

By Company (Trailing 90 Days)

SymbolCompanyTxnsBoughtSoldNet
SYRESpyre Therapeutics, Inc.4$399.7M−$399.7M
ORKAOruka Therapeutics, Inc.4$300.0M−$300.0M
CBIOCRESCENT BIOPHARMA, INC.3$20.0M$20.0M
VRDNViridian Therapeutics, Inc.\DE1$20.0M$20.0M
JBIOJade Biosciences, Inc.1$0

Transactions (13)

DateSymbolTypeSharesValueDescription
2026-07-16CBIOBuy525.9K$7.6MOpen market or private purchase
2026-07-16CBIOBuy853.5K$12.4MOpen market or private purchase
2026-07-01ORKASell42.6K$0Conversion of derivative security
2026-07-01ORKASell3.6M$300.0MOpen market or private sale
2026-07-01ORKABuy3.6M$0Conversion of derivative security
2026-06-23SYRESell16.7K$0Conversion of derivative security
2026-06-23SYREBuy666.7K$0Conversion of derivative security
2026-06-23SYRESell4.7M$399.7MOpen market or private sale
2026-06-09JBIOBuy34.8K$0Grant, award or other acquisition
2026-06-02CBIOBuy11.1K$0Grant, award or other acquisition
2026-06-02ORKABuy9.1K$0Grant, award or other acquisition
2026-05-27SYREBuy8.0K$0Grant, award or other acquisition
2026-05-11VRDNBuy1.2M$20.0MOpen market or private purchase

Activity shown covers the trailing 90 days of SEC Form 4 filings. "Buy" and "sell" follow the SEC acquired/disposed codes and include compensation events (grants, option exercises, tax withholding) unless noted. Historical fact, not investment advice.

Follow Fairmount's next move

Real-time Form 4 alerts, insider track records, and cluster detection — matched to your watchlist.

Start free